September 16, 2013
CASE CCC IN THE NEWS
Taussig Cancer Institute is Giving Clinic's Reach a Big Lift
Cleveland Clinic Starts Trial of Cancer Drug to Treat Alzheimer's Disease
OSU to Open New Triple Negative Breast Cancer Study; Cleveland Clinic, UH and 6 Others Also to Enroll Patients
FDA Panel Backs Pre-Surgery Drug for Breast Cancer
Biomarker May Predict Prostate Cancers Requiring Treatment
Affordable Care Act implementation looms amid hope, speculation
Research on Leptin Receptor Highlighted in Mammary Cell News
An article by Dr. Ofer Reizes, titled Leptin Receptor Maintains Cancer Stem-Like Properties in Triple Negative Breast Cancer Cells, was recently highlighted in "Mammary Cell News". The authors tested the hypothesis that the Leptin Receptor (LEPR), expressed in mammary cancer cells, is necessary for maintaining cancer stem cell-like and metastatic properties. They silenced LEPR via shRNA lentivirus transduction and determined that expression of stem cell self-renewal transcription factors NANOG, SOX2, and OCT4 are inhibited. Co-authors on the study include Qiao Zheng, Lauren Banaszak, Sarah Fracci, Diana Basali, Sarah M Dunlap, Stephen D Hursting, Jeremy N Rich, Anita B Hjelmeland, Amit Vasanji, Nathan A Berger, and Justin D Lathia.
MARK YOUR CALENDARS
Basic Sciences Program Mini-Retreat
The Basic Sciences Program, led by Drs. Clark Distelhorst and Alex Almasan, will be hosting a mini-retreat on Thursday, September 26 from 1-5 pm in WRB 3-136. The retreat will explain the restructuring of the program, feature short, informal presentations, and offer open time to discuss collaborations with other members. All members of the Basic Sciences Program are invited. Please RSVP by Monday, September 23 to email@example.com.
Society for Immunotherapy Regional Conference: Advances in Immunotherapy
The Society for Immunotherapy's regional Advances in Immunotherapy program will be held October 4 at the Intercontinental Hotel and Conference Center at Cleveland Clinic. This CME-accredited program, sponsored by Cleveland Clinic Center for Continuing Medical Education in collaboration with the Case Comprehensive Cancer Center, is specifically designed for the entire unit of care involved in treating cancer. Through several lectures by leading cancer immunologists, this program will summarize central themes in research advances and approvals to facilitate understanding of more sophisticated principles of tumor immunology and immunotherapy, and promote appropriate clinical application. Registration deadline is September 25.
Brain Tumor Funders' Collaborative
The Brain Tumor Funders' Collaborative (BTFC) funding initiative intends to support a fuller characterization of long term survivors based on the physiological, genetic, and molecular characteristics of not just the tumor, but of the entire organism in which a disease occurs (e.g. immunological changes, altered metabolism). The BTFC believes this broad, holistic approach is critical for understanding patient management and for informing clinical trial designs in the highly heterogeneous, noisy background against which interventions are tested. The complicated nature of the problem addressed by this BTFC initiative and the relatively small numbers of long-term survivors indicates to the BTFC that successful applications will require multi-institutional collaborations and extended community outreach accrual efforts.
CTSC Child Health Themed Pilot Awards
The Clinical and Translational Science Collaborative (CTSC) at CWRU seeks applications for pilot research funding from faculty at CWRU, Cleveland Clinic, Metro Health Medical Center, University Hospitals Case Medical Center, and the Louis Stokes Veterans' Administration Medical Center. The primary goal of the Child Health Themed Pilot Award is to support and encourage collaborative research in clinical and translational medicine focused on child health that will lead to both external funding opportunities and new discoveries that will promote and advance child health.
Clinical Assay Development Program
The NCI Clinical Assay Development Program (CADP) is accepting applications from investigators seeking clinical assay development and validation resources. These resources are designed to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. In addition to access to the Institute's assay and validation resources, approved projects will receive project management support.
Biochemistry Student Seminar Series
Pathology Research Seminar Series
Physiology and Biophysics Seminar
Imaging Center Seminar Series
Radiation Oncology Grand Rounds
Hematology and Oncology Research Conference
MetroHealth Research Symposium
Cancer Trainee Seminar
Immunology Journal Club
Prostate Cancer Working Group Seminar Series and Journal Club
Cancer Center Seminar Series canceled
George Stark 80th Birthday Celebration Symposium
Hematology/Oncology Fellows Conference/Curriculum Series
Taussig Cancer Institute Grand Rounds
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
New Directions in Melanoma and Non-Melanoma Skin Cancers
National GvHD Health Symposium
ADDITIONAL UPCOMING SEMINARS & EVENTS
Point of Care Technologies for Cancer
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Alex's Lemonade Stand Foundation 'A' Award
AACR Richard and Hinda Rosenthal Memorial Award
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.